1. Scrip
  2. >>Business
  3. >>Supply Chain

Compounded GLP-1s For Obesity: Is The Genie Out Of The Bottle?

 
• By Cathy Kelly

Patient demand for compounded versions of FDA-approved obesity drugs is unlikely to dissipate, even if semaglutide’s “shortage” status is resolved. The issue likely will continue to be a high-profile concern for the brand industry.

More than two years of brand product shortages have turbocharged a cottage industry. (Shutterstock)
Key Takeaways
  • The business of GLP-1 drug compounding has progressed to a point that will be hard to reverse.

Patient demand for compounded GLP-1 agonists for obesity may have reached a point that will be difficult to reverse, even...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Supply Chain

More from Alimentary/Metabolic